Kerrii B. Anderson Sells 250 Shares of Laboratory Co. of America Holdings (NYSE:LH) Stock

Laboratory Co. of America Holdings (NYSE:LH) Director Kerrii B. Anderson sold 250 shares of the company’s stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $204.13, for a total value of $51,032.50. Following the transaction, the director now directly owns 15,972 shares in the company, valued at approximately $3,260,364.36. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Laboratory Co. of America Price Performance

NYSE:LH opened at $201.32 on Friday. The firm has a market capitalization of $16.97 billion, a price-to-earnings ratio of 40.51, a P/E/G ratio of 1.51 and a beta of 1.02. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.76 and a current ratio of 0.88. The stock has a fifty day moving average of $210.48 and a 200 day moving average of $214.70. Laboratory Co. of America Holdings has a 52-week low of $174.20 and a 52-week high of $234.09.

Laboratory Co. of America (NYSE:LH) last issued its quarterly earnings results on Thursday, April 25th. The medical research company reported $3.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.48 by $0.20. The firm had revenue of $3.18 billion during the quarter, compared to the consensus estimate of $3.12 billion. Laboratory Co. of America had a return on equity of 14.68% and a net margin of 3.52%. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter last year, the company posted $3.82 EPS. On average, research analysts expect that Laboratory Co. of America Holdings will post 14.87 EPS for the current fiscal year.

Laboratory Co. of America Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 12th. Stockholders of record on Tuesday, May 28th will be given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 1.43%. The ex-dividend date of this dividend is Tuesday, May 28th. Laboratory Co. of America’s dividend payout ratio (DPR) is currently 57.95%.

Wall Street Analyst Weigh In

LH has been the topic of a number of research reports. Argus upgraded Laboratory Co. of America from a “hold” rating to a “buy” rating and set a $250.00 price objective on the stock in a research note on Monday, March 25th. SVB Leerink assumed coverage on shares of Laboratory Co. of America in a research note on Monday, February 26th. They set an “outperform” rating and a $260.00 price target on the stock. Robert W. Baird reduced their price objective on shares of Laboratory Co. of America from $255.00 to $244.00 and set an “outperform” rating for the company in a research note on Friday, April 26th. Leerink Partnrs restated an “outperform” rating on shares of Laboratory Co. of America in a research report on Monday, February 26th. Finally, Evercore ISI assumed coverage on Laboratory Co. of America in a research report on Friday, February 9th. They issued an “in-line” rating and a $240.00 price target for the company. Four analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $243.14.

Institutional Trading of Laboratory Co. of America

Hedge funds have recently made changes to their positions in the stock. Provence Wealth Management Group bought a new stake in Laboratory Co. of America in the 3rd quarter worth approximately $29,000. Mendota Financial Group LLC purchased a new position in shares of Laboratory Co. of America during the fourth quarter worth approximately $29,000. Tradewinds Capital Management LLC bought a new stake in shares of Laboratory Co. of America in the 3rd quarter worth approximately $34,000. Exchange Traded Concepts LLC purchased a new stake in shares of Laboratory Co. of America in the 3rd quarter valued at $37,000. Finally, Bruce G. Allen Investments LLC bought a new position in shares of Laboratory Co. of America during the 4th quarter valued at $60,000. 95.94% of the stock is owned by institutional investors.

About Laboratory Co. of America

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS).